Investigational drug · Phase 2
matching dosage
Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Weight Management, Overweight , Obesity, Overweight and/or Obesity.
Phase 2Last checked: Nov 19, 2026Latest source record: Nov 16, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
2
2 still active
All registered trials
8,288
Any phase or sponsor naming "matching dosage"
First trial start
2025
Nov 18, 2025
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "matching dosage", any sponsor or status.
Conditions studied
As listed on its trial records.
- Weight Management
- Overweight , Obesity
- Overweight and/or Obesity
Approved drugs for the same conditions: Obesity and weight management · Cardiovascular and metabolic
Largest trials
Live from ClinicalTrials.gov: studies naming "matching dosage" as an intervention, largest first.
China Medical University HospitalAcademic, hospital or other
NCT07249164 · 343,112 participants · Start Jan 1, 2010 · Primary completion Jul 31, 2025
Drug: Dexmedetomidine · For: Delirium; Cardiac Surgical Procedures; Coronary Artery Bypass Graft (CABG) and 2 more
Sites: Taichung, Taiwan
GlaxoSmithKlineGSK (GSK)
NCT00146835 · 120,794 participants · Start Apr 2003 · Primary completion Jun 2006
Drug: Pediarix; Licensed DTPa containing vaccine and 1 more · For: Hepatitis B; Poliomyelitis; Diphtheria and 2 more
BayerBayer (BAYRY)
NCT03743883 · 99,999 participants · Start Oct 30, 2018 · Primary completion Apr 15, 2019
Drug: Acetylsalicylic Acid(BAYE4465, Aspirin ) · For: Prevention of Oesophagus Cancer and Stomach Cancer
Sites: Multiple Locations, United Kingdom
- A Phase 2b/3, Randomized, Observer-Blinded, Placebo-Controlled, Multicenter Clinical Study Evaluating the Efficacy and Safety of Investigational SARS-CoV-2 mRNA Vaccine CVnCoV in Adults 18 Years of Age and OlderPivotal-lookingCompleted
CureVacIndustry
NCT04652102 · 39,680 participants · Start Dec 11, 2020 · Primary completion Jun 10, 2022
Drug: CVnCoV; Placebo and 1 more · For: Covid19; SARS-CoV-2
Sites: Buenos Aires, Argentina; Mar del Plata, Argentina; Rosario, Argentina · 46 sites in all
- A Controlled Phase 2/3 Study of Adjuvanted Recombinant SARS-CoV-2 Trimeric S-protein Vaccine (SCB-2019) for the Prevention of COVID-19Pivotal-lookingCompleted
Clover Biopharmaceuticals AUS PtyIndustry
NCT04672395 · 31,454 participants · Start Mar 24, 2021 · Primary completion Sep 15, 2022
Drug: CpG 1018/Alum-adjuvanted SCB-2019 vaccine; Placebo; 0.9% saline and 2 more · For: COVID-19
Sites: Alken, Belgium; Brussels, Belgium; Namur, Belgium · 31 sites in all
- A Study to Evaluate Efficacy, Safety, and Immunogenicity of mRNA-1273 Vaccine in Adults Aged 18 Years and Older to Prevent COVID-19Pivotal-lookingCompleted
ModernaTX, Inc.Moderna (MRNA)
NCT04470427 · 30,415 participants · Start Jul 27, 2020 · Primary completion Dec 29, 2022
Drug: mRNA-1273; Placebo · For: SARS-CoV-2
Sites: Birmingham, Alabama; Chandler, Arizona; Glendale, Arizona · 100 sites in all
- Rivaroxaban for the Prevention of Major Cardiovascular Events in Coronary or Peripheral Artery DiseasePivotal-lookingCompleted
BayerBayer (BAYRY)
NCT01776424 · 27,395 participants · Start Feb 28, 2013 · Primary completion Jul 21, 2017
Drug: Rivaroxaban (Xarelto, BAY59-7939); Rivaroxaban (Xarelto, BAY59-7939) and 5 more · For: Prevention & Control
Sites: Birmingham, Alabama; Mobile, Alabama; Anaheim, California · 565 sites in all
Janssen Vaccines & Prevention B.V.Johnson & Johnson (Janssen) (JNJ)
NCT04908683 · 25,236 participants · Start Jul 21, 2021 · Primary completion Jul 21, 2023
Drug: Adenovirus serotype 26 (Ad26)-based respiratory syncytial virus (RSV). preF; Placebo · For: Respiratory Syncytial Viruses; Lower Respiratory Tract Disease
Sites: Birmingham, Alabama; Huntsville, Alabama; Mobile, Alabama · 272 sites in all
- A Study of Milvexian Versus Apixaban in Participants With Atrial FibrillationPivotal-lookingActive, not recruiting
Janssen Research & Development, LLCJohnson & Johnson (Janssen) (JNJ)
NCT05757869 · 20,284 participants · Start Apr 11, 2023 · Primary completion Dec 8, 2026
Drug: Milvexian; Apixaban and 2 more · For: Atrial Fibrillation
Sites: Alexander City, Alabama; Birmingham, Alabama; Dothan, Alabama · 1,052 sites in all
- Clinical Randomisation of an Antifibrinolytic in Significant HaemorrhagePivotal-lookingCompleted
London School of Hygiene and Tropical MedicineAcademic, hospital or other
NCT00375258 · 20,211 participants · Start May 2005 · Primary completion Feb 2010
Drug: Tranexamic acid; Sodium Chloride 0.9% · For: Hemorrhage
Sites: London, United Kingdom
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Also in development for Weight Management
- ElecoglipronPhase 39 trials
AstraZeneca · Type 2 Diabetes Mellitus, Obesity, Overweight
- EcnoglutideXW003, VRB-101Phase 38 trials
Hangzhou Sciwind Biosciences Co., Ltd. · Obesity, Weight Management, OSA - Obstructive Sleep Apnea
- ECC4703Phase 22 trials
Eccogene · Adult Obesity, Weight Management, Metabolic Dysfunction-associated Steatohepatitis
- GV101Phase 22 trials
Graviton Bioscience Corporation · Friedreich's Ataxia, Weight Management
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.